🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Changsha
Clinical trial register · China

Clinical Trials in Changsha, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 52 Guangzhou 44 Wuhan 26 Shanghai 25 Changsha 24
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Xiangya Hospital of Central South University49 Eli Lilly and Company36 Second Xiangya Hospital of Central South University36 Hunan Province Tumor Hospital32 Clear sponsor filter
Site location
Beijing52 Guangzhou44 Wuhan26 Shanghai25 Changsha24
All 67 locations
Target enrolment
to

Trials with a site in Changsha

24 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT07227415Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm
Pfizer
Phase 1/2
224
Beijing, Chongqing, Wuhan, Changsha, Nanjing, Jinan, Ningbo
2026-02-10
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site
Pfizer
Phase 3
800
Hefei, Beijing, Chongqing, Guangzhou, Meizhou, Nanning, Wuhan, Changsha
2025-12-11
Recruiting
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
NCT06807281Atopic Dermatitis
Pfizer
Phase 3
500
Beijing, Shenzhen, Changsha, Nanchang, Hangzhou, Shanghai
2025-12-02
Active, closed
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
NCT07073820Pulmonary Hypertension
Pfizer
Phase 2
42
Guangzhou, Changsha, Nanjing, Shanghai
2025-11-10
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Pfizer
Phase 3
1,000
Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Wuhan, Changsha, Huai'an
2025-09-28
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 1
540
Changsha
2025-08-20
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965Breast Cancer
Pfizer
Phase 3
400
Hefei, Fuzhou, Guangzhou, Baoding, Wuhan, Changsha, Nanjing, Dalian
2025-08-05
Active, closed
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711Severe Alopecia Areata
Pfizer
Phase 3
208
Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Chengdu, Kunming, Hangzhou
2025-07-31
Recruiting
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
NCT06807268Eczema
Pfizer
Phase 3
150
Beijing, Shenzhen, Changsha, Nanchang, Shanghai, Hangzhou
2025-07-24
Recruiting
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
NCT06991257Heart Failure
Pfizer
Phase 2
620
Beijing, Lanzhou, Guangzhou, Haikou, Shijiazhuang, Changsha, Changchun, Xi'an
2025-06-19
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945Alopecia Areata
Pfizer
Phase 3
674
Beijing, Chongqing, Guangzhou, Changsha, Nanchang, Shanghai, Chengdu, Kunming
2025-04-01
Recruiting
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
NCT06679140COVID-19 SARS-CoV-2 Infection
Pfizer
Phase 3
2,330
Chizhou, Beijing, Xiamen, Guangzhou, Nanning, Changsha, Nanchang, Changchun
2024-12-08
Active, closed
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194Migraine
Pfizer
Phase 3
200
Beijing, Chongqing, Guangzhou, Jingzhou, Wuhan, Changsha, Suzhou, Wuxi
2024-11-15
Active, closed
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
NCT06531109Alopecia Areata
Pfizer
Observational
450
Beijing, Changchun, Changsha, Guangzhou, Shanghai
2024-08-07
Active, closed
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632Advanced or Metastatic Breast Cancer
Pfizer
Phase 2
333
Wuhan, Changsha, Shanghai
2024-01-09
Active, closed
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Pfizer
Phase 3
1,571
Beijing, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Nanyang, Wuhan, Changsha
2023-11-08
Recruiting
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
NCT05995964Atopic Dermatitis
Pfizer
Phase 2
340
Beijing, Fuzhou, Dongguan, Guangzhou, Shijiazhuang, Changsha, Wuhan, Zhenjiang
2023-08-22
Recruiting
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
NCT05895786Myositis
Pfizer
Phase 3
318
Hefei, Beijing, Dongguan, Guangzhou, Cangzhou, Changsha, Nanjing, Nanchang
2023-05-20
Active, closed
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
NCT05382364Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer
Pfizer
Phase 1
25
Harbin, Changsha, Changchun, Shanghai, Tianjin
2022-06-29
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Active, closed
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
NCT04821622Prostate Cancer
Pfizer
Phase 3
599
Hefei, Beijing, Lanzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing
2021-05-12
Active, closed
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421Neoplasms
Pfizer
Phase 3
841
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Nanjing
2020-12-21
Active, closed
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
NCT04165317Non-muscle Invasive Bladder Cancer
Pfizer
Phase 3
1,068
Hefei, Beijing, Fuzhou, Wuhan, Changsha, Nanjing, Nantong, Suzhou
2019-12-30
Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
Pfizer
Phase 1
453
Guangzhou, Changsha, Nanjing, Chengdu, Wenzhou
2018-04-17
Rows per page Showing 1–24 of 24
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/changsha

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 24 of those studies with a site in Changsha that also match the filters currently applied.

How many clinical trials are recruiting in Changsha?

13 of the 24 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 11 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Changsha), 24 studies
PhaseStudiesRecruitingShare
Phase 314858.3%
Phase 24216.7%
Phase 13212.5%
Observational104.2%
Phase 1/2114.2%
Phase 4104.2%

Most active sponsors

Lead sponsors with the most studies (Changsha)
Lead sponsorStudiesRecruiting
Pfizer2413
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.